Ovid Therapeutics (OVID)

• Market cap: $70.9M
• 1 day: 3.35%
• 5 days: -5.78%
• 1 month: -8.38%
• 3 months: -10.83%
• 6 months: 40.15%
• Year to date: -69.92%
• 1 year: -70.54%
• 5 years: -79.70%
• 10 years: -91.85%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Employees: 25

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

262% more call options, than puts

Call options by funds: $47K | Put options by funds: $13K

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

54% more capital invested

Capital invested by funds: $29.7M [Q2] → $45.8M (+$16.1M) [Q3]

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

1% more funds holding

Funds holding: 73 [Q2] → 74 (+1) [Q3]

0.31% more ownership

Funds ownership: 54.35% [Q2] → 54.66% (+0.31%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 200% upside
• Avg. target: $3 200% upside
• High target: $3 200% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 117 / 313 met price target

200% upside $3

Buy Reiterated

4 Dec 2024